Reversal of Bone Loss with Percutaneous Oestrogens

  • T. Garnett
  • M. Savvas
  • J. W. W. Studd
Conference paper

Abstract

It is now accepted that oestrogen replacement therapy after the menopause is effective in preventing the rapid loss of bone which occurs following the cessation of ovarian function [1–4]. Although maintenance of bone mass is sufficient for recently postmenopausal women, it may be inadequate for woman many years past the menopause who have lost a significant proportion of their bone mass. For such women, who have already developed osteoporosis and suffered a fracture, hormone replacement is often not advised as it is considered too late to have any beneficial effect on the skeleton. Nothing will reverse the loss of height and “Dowager’s hump” characteristic of the disease, but if it is possible to increase bone density to above the “fracture threshold” oestrogen therapy should be given despite the increased incidence of side effects in patients of this age. The disadvantages of a monthly withdrawal bleed may be an acceptable price to pay if greater bone strength is achieved (Fig. 22.1).

Keywords

Estrogen Osteoporosis Testosterone Progesterone Oestradiol 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clark AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976; ii:1038–9.CrossRefGoogle Scholar
  2. 2.
    Nachtigall LE, Nachtigall H, Nachtigall RD, Beckman ME. Estrogen replacement therapy 1: a 10-year prospective study in the relationship to osteoporosis. Obstet Gynecol 1979; 53:277–81.PubMedGoogle Scholar
  3. 3.
    Christiansen C, Christensen S, McNair P, Hagen C. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980; 10:273–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Ettinger B, Genant HK, Cann CE. Post-menopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med 1987; 106:40–5.PubMedGoogle Scholar
  5. 5.
    Munk-Jensen N, Nielsen SP, Obel EB, Eriksen PB. Reversal of postmenopausal vertebral bone loss by oestrogen and progestogen: a double-blind placebo controlled study. Br Med J 1988; 296:1150–2.CrossRefGoogle Scholar
  6. 6.
    Gallagher JC, Goldgar D, Kable WT. Comparison of estrogen and progestin therapy on cortical and trabecular bone using SPA, DPA and OCT. Sixth international workshop on bone and soft tissue. 1989.Google Scholar
  7. 7.
    Civitelli R, Agunsdei D, Nardi P, Zacchei F, Avioli LV, Gennari C. Effects of one-year treatment with estrogens on bone mass, intestinal calcium absorption, and 25-hydroxyvitamin D-1cx-hydroxylase reserve in postmenopausal osteoporosis. Calcif Tissue Int 1988; 42:77–86.PubMedCrossRefGoogle Scholar
  8. 8.
    Adami S, Suppi, R, Bertoldo F, Rossini M, Residori M, Maresca V, Lo Cascio V. Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 1989; 7:79–86.PubMedCrossRefGoogle Scholar
  9. 9.
    Ribot C, Pouilles JM, Tremollieres F. Prevention of postmenopausal bone loss by transdermal 17ß-estradiol: a two year longitudinal study. Proceedings of the XIIth world congress of obstetrics and gynaecology. Rio de Janeiro, Brazil, 1988.Google Scholar
  10. 10.
    Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R. Transdermal administration of 17ß-estradiol in postmenopausal women: preliminary results of a longitudinal study. In: Christiansen C, Johansen JS, Riss BJ, eds. Osteoporosis. International symposium on osteoporosis, Denmark, 1987.Google Scholar
  11. 11.
    Riis BJ, Thomsen K, Stom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987; 156:61–5.PubMedGoogle Scholar
  12. 12.
    McKay Hart D, Al-Azzawi F, Farish E et al. Effect of ossopan alone, oestradiol implants alone or both therapies combined on bone density and bone biochemistry in oophorectomised women. In: Christiansen C, Johansen JS, Riis BJ, eds. Osteoporosis, International Symposium on Osteoporosis, Denmark, 1987.Google Scholar
  13. 13.
    Treasure J, Russell G, Fogelman I, Muyroy B. Reversal of bone loss in anorexia nervosa. Br Med J 1987; 295:474–5.CrossRefGoogle Scholar
  14. 14.
    Greenspan SL, Neer RM, Ridgway EC, Klibanski A. Osteoporosis in men with hyperpro-lactinemic hypogonadism. Ann Intern Med 1986; 104:777–82.PubMedGoogle Scholar
  15. 15.
    Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Serge GV, Crowley WF. Increases in bone density during treatment of men with idipoathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Matta WH, Shaw RW, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypo-oestrogenism with the GnRH analogue Buserelin in premenopausal women. Clin Endocrinol 1988; 29:45–51.CrossRefGoogle Scholar
  17. 17.
    Savvas M, Studd JWW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988; 297:331–3.CrossRefGoogle Scholar
  18. 18.
    Savvas M, Watson NR, Garnett T, Fogelman I, Studd JWW. A prospective study of the effects of oestradiol implants on the bone density of post-menopausal women. Br J Obstet Gynaecol (in press).Google Scholar
  19. 19.
    Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17β-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol 1985; 152:1099.PubMedGoogle Scholar
  20. 20.
    Sitruk-Ware R, de Ligniere B, Basdevant A, Mauvais-Jarvis P. The absorption of percutaneous oestradiol in post-menopausal women. Maturitas 1980; ii:207–11.CrossRefGoogle Scholar
  21. 21.
    Lindsay R, Coots JRT, Hart DH. The effect of endogenous oestrogen on plasma and urinary calcium and phosphate in oophorectomised women. Clin Endocrinol 1977; 6:87.CrossRefGoogle Scholar
  22. 22.
    Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63:759–63.PubMedGoogle Scholar
  23. 23.
    Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983; 309:1405–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis, its clinical features. JAMA 1941; 116:2465–74.CrossRefGoogle Scholar
  25. 25.
    Brincat M, Versi E, Moniz CF, Magos A. deTrafford J, Studd JWW. Skin collagen changes in postmenopausal women receiving different regimens of estrogen therapy. Obstet Gynecol 1987; 70:123–7.PubMedGoogle Scholar
  26. 26.
    Ernst H, Heath J, Rodan G. Estradiol effects on proliferative messenger ribonucleic acid for collagen and insulin-like growth factor 1, and parathyroid hormone stimulated adenylate cycle activation in osteoblastic cells for caliane and long bones. Endocrinology 1984; 124:825–33.Google Scholar
  27. 27.
    Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314:1676–86.PubMedCrossRefGoogle Scholar
  28. 28.
    Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper B, Rao DS. Relationships between surface, volume and thickness of iliac trabecular bone in aging and in osteoporosis. J Clin Invest 1983;72:1396–409.PubMedCrossRefGoogle Scholar
  29. 1.
    Savvas M, Studd JWW, Fogelman I, Dooley M, Montgomery J, Murby B. Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988; 297:331–3.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 1990

Authors and Affiliations

  • T. Garnett
  • M. Savvas
  • J. W. W. Studd

There are no affiliations available

Personalised recommendations